Dear Colleagues,

Cerebral and cardiovascular diseases are the main cause of death or disability in developed countries, especially in the elderly population. The same thing is happening now for hemophilia patients who have thus been able to achieve a life expectancy comparable to that of the general population, thanks to the improvement of hemostatic therapies and the early management of the disease. In recent years in our Centers the number of elderly patients suffering simultaneously from bleeding disorders and cerebral/cardiovascular diseases (e.g. atrial fibrillation) is constantly increasing. Antihemorrhagic and antithrombotic drugs are often used together, so it is necessary know which are the most suitable in the treatment of these particular patients, with which dosage and therapy scheme.

The aim of this brief survey is to investigate how many hemophilia patients with cerebro/cardiovascular diseases are currently treated in the different centers, which drugs are used, which benefits and adverse events of the different treatments. The survey would be the starting point for a more in-depth International Registry aimed at creating management protocols shared by the different clinicians.

You are therefore encouraged to participate in this brief survey in which can be found at the following link: https://redcap.isth.org/surveys/?s=9PXYLWAHXA

Thank you for your support and contribution!

Samantha Pasca
MD, MSc
Hemophilia Center - Padua University Hospital (Italy)